FDA Approves New Label for Stiolto Respimat Showing Efficacy Against COPD Flare-ups

The U.S. Food and Drug Administration (FDA) approved a new label for Stiolto Respimat (a combination therapy of tiotropium bromide and olodaterol) based on data from clinical trials showing a significant reduction in the frequency of chronic obstructive pulmonary disease (COPD) exacerbations driven by tiotropium, the active ingredient of …

Treatment with Spiolto Respimat Reduces Rate of COPD Flare-ups Compared to Spiriva Respimat, Study Shows

Treatment of chronic obstructive pulmonary disease (COPD) patients with Spiolto Respimat (tiotropium/olodaterol) reduced the rate of moderate-to-severe exacerbations, compared to Spiriva Respimat (tiotropium bromide), in a Phase 3 clinical trial, according to Boehringer Ingelheim, the manufacturer of both therapies. The results were published in the journal The Lancet Respiratory Medicine,…